Post-earnings recap
Reported
Wed, May 6, 2026
EPS actual
$-0.49
EPS est.
$-0.56
EPS surprise
+12.50%
1-day move
+0.61%
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Castle Biosciences reported a loss per share that was better than expected, which led to a slight increase in the stock price by 0.61%. However, there was no revenue reported, leaving investors without a complete picture of the company's performance. The lack of management commentary and guidance may create uncertainty for investors moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.49 | N/A | +12.50% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based solely on numerical results.